Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pardoprunox vs Pramipexole in Advanced Parkinson's Disease
NCT00903838Phase 2Terminated
- Sponsor
- Abbott Laboratories
- Start
- Sep 2009
- Primary completion
- May 2011
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of pardoprunox in Parkinson's disease (PD) (2 arms), sponsored by Abbott Laboratories. Primary endpoint: Change from baseline to endpoint in ON-time without dyskinesia at 16 weeks. Started Sep 2009; status: terminated.
02
Drugs
pardoprunox
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT00903838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00903838.